Xencor, Inc Net Change in Cash
Xencor, Inc (XNCR) reported Net Change in Cash of -$9.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-05
- Xencor, Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$40.00M.
- Xencor, Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$1.30M.
- Xencor, Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$22.75M, a 223.31% decline year-over-year.
- Xencor, Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $18.45M.
- Xencor, Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $13.10M.
- Xencor, Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$12.91M, a 5761.40% decline from fiscal 2023.
- Xencor, Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $228.00K.
- Xencor, Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$89.54M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.51M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$40.00M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $13.10M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | -$12.68M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $3.47M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | -$1.30M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$12.91M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | -$24.75M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | -$23.02M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$22.75M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $228.00K 10-K · filed 2026-02-25 | |||
| 2023-09-30 | -$831.00K 10-Q/A · filed 2025-02-24 | |||
| 2023-06-30 | -$19.23M 10-Q/A · filed 2025-02-24 | |||
| 2023-03-31 | $18.45M 10-Q/A · filed 2025-02-24 | |||
| 2022-12-31 | -$89.54M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$90.83M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | -$94.07M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$65.21M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$20.06M 10-K/A · filed 2025-02-24 | |||
| 2021-09-30 | -$122.34M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | -$47.70M 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | $13.42M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $113.23M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $7.78M 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | $59.22M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $23.50M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $24.07M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $24.94M 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $6.31M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | -$4.39M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $9.72M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $18.47M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $18.76M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $235.04M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $2.00M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | -$894.00K 10-Q · filed 2018-11-05 | |||
| 2017-06-30 | -$3.31M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $1.94M 10-K · filed 2019-02-26 | |||
| 2015-12-31 | $1.94M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |